ID24264A - COMPOSITION CONSIST OF 5- [4- [2- (N-METHYL-N-2-PYRIDYL) AMINO) ETHOCYSIE [BENZIL] TIAZOLIDIN-2,4-DION - Google Patents

COMPOSITION CONSIST OF 5- [4- [2- (N-METHYL-N-2-PYRIDYL) AMINO) ETHOCYSIE [BENZIL] TIAZOLIDIN-2,4-DION

Info

Publication number
ID24264A
ID24264A IDW991520A ID991520A ID24264A ID 24264 A ID24264 A ID 24264A ID W991520 A IDW991520 A ID W991520A ID 991520 A ID991520 A ID 991520A ID 24264 A ID24264 A ID 24264A
Authority
ID
Indonesia
Prior art keywords
ethocysie
tiazolidin
dion
benzil
pyridyl
Prior art date
Application number
IDW991520A
Other languages
Indonesian (id)
Inventor
Jeffrey Roger Granett
Original Assignee
Smithkline Beecham P L C Cs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9712851.6A external-priority patent/GB9712851D0/en
Application filed by Smithkline Beecham P L C Cs filed Critical Smithkline Beecham P L C Cs
Publication of ID24264A publication Critical patent/ID24264A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
IDW991520A 1997-06-05 1998-06-02 COMPOSITION CONSIST OF 5- [4- [2- (N-METHYL-N-2-PYRIDYL) AMINO) ETHOCYSIE [BENZIL] TIAZOLIDIN-2,4-DION ID24264A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9711683.4A GB9711683D0 (en) 1997-06-05 1997-06-05 Composition
GBGB9712851.6A GB9712851D0 (en) 1997-06-18 1997-06-18 Composition
PCT/EP1998/003478 WO1998055122A1 (en) 1997-06-05 1998-06-02 Composition comprising 5-[4-[2-(n-methyl-n-2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione

Publications (1)

Publication Number Publication Date
ID24264A true ID24264A (en) 2000-07-13

Family

ID=26311662

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW991520A ID24264A (en) 1997-06-05 1998-06-02 COMPOSITION CONSIST OF 5- [4- [2- (N-METHYL-N-2-PYRIDYL) AMINO) ETHOCYSIE [BENZIL] TIAZOLIDIN-2,4-DION

Country Status (29)

Country Link
EP (1) EP0998284A1 (en)
JP (1) JP2001521553A (en)
KR (1) KR20010013410A (en)
CN (3) CN1112926C (en)
AP (1) AP1214A (en)
AR (2) AR008198A1 (en)
AU (1) AU8215098A (en)
BG (1) BG104048A (en)
BR (1) BR9810405A (en)
CA (2) CA2333352A1 (en)
CO (1) CO4940400A1 (en)
DZ (1) DZ2510A1 (en)
EA (1) EA002384B1 (en)
GB (1) GB9711683D0 (en)
HU (1) HUP0004070A3 (en)
ID (1) ID24264A (en)
IL (1) IL133074A0 (en)
MX (1) MXPA99011322A (en)
NO (2) NO995938L (en)
NZ (2) NZ523725A (en)
OA (1) OA11306A (en)
PE (1) PE78899A1 (en)
PL (1) PL337201A1 (en)
SK (1) SK164899A3 (en)
TR (2) TR199902963T2 (en)
TW (1) TW570797B (en)
UY (1) UY25032A1 (en)
WO (1) WO1998055122A1 (en)
ZA (2) ZA9811572B (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200103061T2 (en) 1999-04-23 2002-05-21 Smithkline Beecham P.L.C. New pharmaceutical ingredient.
US20040248945A1 (en) 1999-04-23 2004-12-09 Smithkline Beecham P.L.C. Thiazolidinedione derivative and its use as antidiabetic
EP1173435B1 (en) * 1999-04-23 2003-07-30 SmithKline Beecham plc Polymorph of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt
GB0021978D0 (en) 2000-09-07 2000-10-25 Smithkline Beecham Plc Novel pharmaceutical
GB0127805D0 (en) * 2001-11-20 2002-01-09 Smithkline Beecham Plc Pharmaceutical composition
WO2003050112A1 (en) * 2001-12-13 2003-06-19 Smithkline Beecham Plc Toluenesulfonate hydrates of a thiazolidinedione derivative
GB0129876D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
GB0129871D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
GB0130509D0 (en) * 2001-12-20 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
EP2270007A1 (en) * 2006-05-09 2011-01-05 Teva Pharmaceutical Industries Ltd. 2-N-{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2-4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
US7435741B2 (en) 2006-05-09 2008-10-14 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
WO2015008234A1 (en) * 2013-07-17 2015-01-22 Glenmark Pharmaceuticals S.A. Bicyclic heterocyclic compounds as ror gamma modulators

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE186724T1 (en) * 1987-09-04 1999-12-15 Beecham Group Plc SUBSTITUTED THIAZOLIDINEDIONE DERIVATIVES
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
WO1995021608A1 (en) * 1994-02-10 1995-08-17 Smithkline Beecham Plc Use of insulin sensitisers for treating renal diseases
SK16498A3 (en) * 1995-08-10 1999-03-12 Warner Lambert Co A method of reducing the amount of exogenous insulin administered to a patient having noninsulin-dependent diabetes mellitus
WO1997018811A1 (en) * 1995-11-17 1997-05-29 Warner-Lambert Company A method of treating myotonic dystrophy
NZ314406A (en) * 1996-03-18 2000-12-22 Sankyo Co Treatment or prophylaxis of pancreatitis with a medicament containing an insulin sensitiser including oxazoles and thiazoles
WO1998002159A1 (en) * 1996-07-12 1998-01-22 Smithkline Beecham Plc Novel treatment of leptine resistance

Also Published As

Publication number Publication date
AR015120A1 (en) 2001-04-18
AR008198A1 (en) 1999-12-29
EP0998284A1 (en) 2000-05-10
CA2292629C (en) 2004-01-06
UY25032A1 (en) 1998-11-26
BG104048A (en) 2000-07-31
PL337201A1 (en) 2000-08-14
AU8215098A (en) 1998-12-21
NO20040738L (en) 2000-02-02
TW570797B (en) 2004-01-11
AP9901696A0 (en) 1999-12-31
EA199901116A1 (en) 2000-06-26
CN1526391A (en) 2004-09-08
BR9810405A (en) 2000-08-29
ZA9811572B (en) 1999-07-22
OA11306A (en) 2003-10-22
HUP0004070A2 (en) 2002-02-28
CN1430959A (en) 2003-07-23
TR200002790T2 (en) 2001-11-21
NZ523725A (en) 2004-09-24
TR199902963T2 (en) 2000-02-21
NZ513922A (en) 2001-09-28
CN1259050A (en) 2000-07-05
CA2333352A1 (en) 1998-12-10
DZ2510A1 (en) 2003-01-25
NO995938L (en) 2000-02-02
NO995938D0 (en) 1999-12-03
CN1112926C (en) 2003-07-02
WO1998055122A1 (en) 1998-12-10
KR20010013410A (en) 2001-02-26
ZA984826B (en) 1999-08-03
SK164899A3 (en) 2000-11-07
CA2292629A1 (en) 1998-12-10
MXPA99011322A (en) 2004-12-02
JP2001521553A (en) 2001-11-06
HUP0004070A3 (en) 2002-03-28
GB9711683D0 (en) 1997-08-06
IL133074A0 (en) 2001-03-19
PE78899A1 (en) 1999-10-22
AP1214A (en) 2003-10-08
EA002384B1 (en) 2002-04-25
CO4940400A1 (en) 2000-07-24

Similar Documents

Publication Publication Date Title
DE69718480D1 (en) HETEROCYCLIC METALLOPROTEASE INHIBITORS
DE69824199D1 (en) LACTAM COMPOUNDS AS METALLOPROTEASE INHIBITORS
DK0923561T3 (en) Heterocyclic metalloprotease inhibitors
ATE485283T1 (en) TYPE 1 11-BETA-HYDROXY-STEROID DEHYDROGENASE INHIBITORS
DE69940115D1 (en) HETEROCYCLIC INHIBITORS OF P38
NO20021116D0 (en) New composition
DE69830410D1 (en) META BENZAMIDINE DERIVATIVES AS SERINE PROTEASE INHIBITORS
DK1114051T3 (en) Inhibitors of p38
MA26500A1 (en) NEW FORM OF S-OMERPRAZOLE
EE200200132A (en) Novel spiroheterocyclic compounds useful as reversible inhibitors of cysteine proteases
NO20021115D0 (en) New composition
DE60009675D1 (en) COMPOSITION CONTAINING PROTON PUMP INHIBITORS
ID24264A (en) COMPOSITION CONSIST OF 5- [4- [2- (N-METHYL-N-2-PYRIDYL) AMINO) ETHOCYSIE [BENZIL] TIAZOLIDIN-2,4-DION
ATE333866T1 (en) DISPERSION FORMULATIONS CONTAINING LIPASE INHIBITORS
DK0928291T3 (en) 3-Mercaptoacetylamino-1,5-substituted 2-oxo-azepane derivatives useful as inhibitors of matrix metalloproteinase
ID24267A (en) ENANSIOMERS OF 4 - [[(SIANOIMINO) [(1,2,2-TRIMETHYLOPOPIL) AMINO] METHYL] AMINO] BENZONITRIL
FIU990494U0 (en) New composition
DK0928192T3 (en) High-release active substance antimycotic gel
BR9710322A (en) Substituted N- (5-isothiazolyl) thioamides
DK0888340T3 (en) 4- (Benzo-1,3-dioxolyl) -pyrrolidine-3-carboxylic acid derivatives as antagonists of enodthelin
ID24081A (en) COMPOUNDS 5- (2-IMIDAZOLINILAMINO) BENZIMIDAZOL USING AS ALFA-2-ADRENOSEPTOR AGONISTS
DK0944601T3 (en) Heterocyclic quanidinylamino compounds as alpha-2-adrenoceptor agonists
DK1150976T3 (en) 3- (Thiosubstituted amido) lactams useful as inhibitors of matrix metalloproteinase
AU7673800A (en) Hydrated N-(3-((2-(3,4-dimethoxyphenyl) ethyl) amino) propyl) -4-nitro benzamidehydrochloride and its use in pharmaceutical compositions
AU2001290743A1 (en) Solid salt forms of n-(2-(4-(2-(1-methylethoxy)phenyl)-1-piperazinyl)ethyl)-2-oxo-1-piperidineacetamide